01. Doctor Overview
Dr. David J. Kwiatkowski is a thoracic oncology specialist who serves as senior physician at Dana-Farber Cancer Institute/Brigham and Women’s Hospital in Boston, Massachusetts. He also holds an academic post of professor of medicine at Harvard Medical School. Prior to joining the staff at Dana-Farber Cancer Institute in 1991, Dr. Kwiatkowski was employed by Massachusetts General Hospital (MGH).
As a thoracic oncology specialist, Dr. Kwiatkowski’s clinical focus is on thoracic malignancies, among them thymic cancer, lung cancer, and mesothelioma. He is board-certified in both internal medicine and medical oncology. Dr. Kwiatkowski’s research interests revolve around individualized and targeted therapies for cancers based on their mutations. He is particularly interested in mesothelioma treatment strategies and is actively involved on several fronts in developing clinical trials and novel approaches to therapy for this rare malignancy.
02. Fast Facts
Doctor Fast Facts
Main Speciality: Oncology
Other Interests & Specialties: Hematologic oncology, cancer genetics, lung cancer, mesothelioma, personalized and targeted therapies for lung cancer and mesothelioma.
Certifications, Awards & Accolades: American Board of Internal Medicine Certifications for Internal Medicine and Oncology, NIH NINDS Javits Neuroscience Investigator Award, Program Leader at the Dana Farber Harvard Cancer Center Cancer Genetics Program, The LAM Foundation Scientific Advancement Award, Manuel R. Gomez Award of the Tuberous Sclerosis Alliance, Harvard Medical School Excellence in Tutoring Award, ASCI Member, Super Doc Award, Janeway Prize
Education & Experience:
- Residency and fellowship for hematology/oncology at Massachusetts General Hospital
- Medical Degree from Columbia University College of Physicians & Surgeons
Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma. Oncogene. June 2014;33:3151-3160. doi: 10.1038/onc.2013.280
Identification of a transcriptional profile associated with in vitro invasion in non-small cell lung cancer cell lines. Cancer and Biology Therapy. April 2004;3(7):624-631. doi: 10.4161/cbt.3.7.914
The Introduction of Systematic Genomic Testing for Patients with Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology. December 2012;7(12):1767-1774. doi: 10.1097/JTO.0b013e3182745bcb